Ann: MLA Subsidiary to help Develop Canine Cancer Treatment, page-6

I bought into MLA recently. I think it was overhyped and then oversold. The vendors of MediVet sold their business for $11m in an all scrip deal at 30c - that stake is now worth closer to $3m at current prices. That is a strong incentive!

The previous 4C showed strong positive cash flow, expectations for growth and costs under control. The blue sky story is in MediVet - the market there in the US is huge. The human healthcare division also looks to be starting to achieve some growth.

Will post more comments after the next update.